Alnylam Pharmaceuticals
ALNY
#650
Rank
โ‚ฌ29.27 B
Marketcap
226,97ย โ‚ฌ
Share price
-7.14%
Change (1 day)
45.25%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -โ‚ฌ0.17 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are โ‚ฌ2.09 Billion. In 2023 the company made an earning of -โ‚ฌ0.3 Billion, an increase over its 2022 earnings that were of -โ‚ฌ0.93 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -โ‚ฌ0.17 Billion-43.12%
2023 -โ‚ฌ0.3 Billion-67.84%
2022 -โ‚ฌ0.93 Billion36.93%
2021 -โ‚ฌ0.68 Billion-8.04%
2020 -โ‚ฌ0.74 Billion-15.66%
2019 -โ‚ฌ0.87 Billion12.23%
2018 -โ‚ฌ0.78 Billion62.91%
2017 -โ‚ฌ0.48 Billion17.78%
2016 -โ‚ฌ0.41 Billion43.44%
2015 -โ‚ฌ0.29 Billion60.69%
2014 -โ‚ฌ0.18 Billion98.2%
2013 -โ‚ฌ88.09 Million
2011 -โ‚ฌ51.96 Million27.48%
2010 -โ‚ฌ40.76 Million-10.92%
2009 -โ‚ฌ45.75 Million95.77%
2008 -โ‚ฌ23.37 Million
2006 -โ‚ฌ37.44 Million-9.13%
2005 -โ‚ฌ41.2 Million34.74%
2004 -โ‚ฌ30.58 Million36.79%
2003 -โ‚ฌ22.36 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-โ‚ฌ0.5 Billion 181.30%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ4.70 B-2,759.15%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ58.96 M-133.30%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚ฌ0.24 Billion 30.91%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚ฌ33.17 Million-81.27%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ12.06 B-6,912.96%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
โ‚ฌ7.02 B-4,063.98%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚ฌ0.78 B-542.53%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel